OR WAIT 15 SECS
Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash.
Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash, it was announced in an Oct. 21, 2019 press release.
The transaction, which is approximately worth $750 million, will include the label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses. The agreement is subject to Danaher’s acquisition of the GE Biopharma business, in addition to any related regulatory approvals.
“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius,” said Joachim Kreuzburg, Sartorius’ CEO, in the press release. “With the Octet platform of FortéBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. The chromatography hardware and resins and the microcarrier businesses broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”